Pacific Biosciences Of California (PACB) Capital Expenditures Growth (3y) (2013 - 2026)
Pacific Biosciences Of California (PACB) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.20 Bn | 175.91 Bn | 6.27 Bn | 1.64% |
| 2 | Stryker | 128.87 Bn | 125.99 Bn | 3.81 Bn | 8.49% |
| 3 | Medtronic | 108.88 Bn | 99.66 Bn | 6.41 Bn | 8.89% |
| 4 | Boston Scientific | 68.33 Bn | 66.87 Bn | 3.61 Bn | 16.83% |
| 5 | Edwards Lifesciences | 47.31 Bn | 43.64 Bn | 1.29 Bn | 1.81% |
| 6 | Dexcom | 28.65 Bn | 27.53 Bn | 750.30 Mn | 0.84% |
| 7 | GE HealthCare Technologies | 28.40 Bn | 26.11 Bn | 1.98 Bn | 7.57% |
| 8 | Smith & Nephew | 26.97 Bn | 26.40 Bn | - | - |
| 9 | Koninklijke Philips | 25.55 Bn | 22.42 Bn | 2.07 Bn | 2.15% |
| 10 | Pacific Biosciences Of California | 418.97 Mn | 143.01 Mn | 12.84 Mn | -6.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.49% |
| Dec 31, 2025 | -44.00% |
| Sep 30, 2025 | -26.42% |
| Jun 30, 2025 | -48.47% |
| Mar 31, 2025 | -27.45% |
| Dec 31, 2024 | -17.14% |
| Jun 30, 2024 | -1.95% |
| Mar 31, 2024 | 113.07% |
| Dec 31, 2023 | 211.44% |
| Sep 30, 2023 | 15.69% |
| Jun 30, 2023 | 92.29% |
| Mar 31, 2023 | 216.83% |
| Dec 31, 2022 | 226.42% |
| Sep 30, 2022 | 71.60% |
| Jun 30, 2022 | 87.16% |
| Mar 31, 2022 | 42.66% |
| Dec 31, 2021 | 265.93% |
| Jun 30, 2021 | 4.98% |
| Mar 31, 2021 | 5.24% |
| Dec 31, 2020 | -60.17% |